1st Quarter - Report

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING for SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

21st Century Cures initiative generally; and the creation of a new imaging drug approval pathway at the FDA specifically.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
CAITLIN BLAKE KUBLER —

Contacted: SENATE; Nuclear Regulatory Commission (NRC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Energy, Dept of; Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Nuclear medicine reimbursement generally and nuclear medicine APC's under HOPPS specifically. Sustainable growth rate provisions of H.R. 2, the "Medicare Access and CHIP Reauthorization Act of 2015."

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JESSE SCHOOLNIK —

Contacted: Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Nuclear Regulatory Commission (NRC); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Energy, Dept of

Bills named: H.R. 2 (114th)

Energy/Nuclear ENG

Domestic isotope supply issues generally, including oversight of the American Medical Isotope Production Act of 2011. Medical radiation issues generally, including Nuclear Regulatory Commission regulations.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JESSE SCHOOLNIK —

Contacted: Energy, Dept of; SENATE; Food & Drug Administration (FDA); Nuclear Regulatory Commission (NRC); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Energy/Water and Labor/HHS/Education appropriations generally for DOE and NIH funding opportunities for nuclear medicine.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
CAITLIN BLAKE KUBLER —
JESSE SCHOOLNIK —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Energy, Dept of; Centers For Medicare and Medicaid Services (CMS); Nuclear Regulatory Commission (NRC)

Pharmacy PHA

Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
CAITLIN BLAKE KUBLER —

Contacted: Office of Science & Technology Policy (OSTP); Nuclear Regulatory Commission (NRC); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Energy, Dept of; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.